Many of the participants lost more than 20% of their weight
Manufacturer Assistance Programs : Pharmaceutical companies such as Novo Nordisk and Eli Lilly offer patient assistance programs (PAPs) that can significantly reduce or even eliminate the cost of GLP-1 medications for eligible patients
For gastrointestinal symptoms , which represent the most common side effects: Eat smaller, more frequent meals rather than large portions Avoid high-fat, greasy, or spicy foods that may exacerbate nausea Stay well-hydrated, particularly if experiencing vomiting or diarrhoea Consider eating bland foods (toast, crackers, rice) when nauseous Take anti-emetic medications if prescribed by your doctor Allow adequate time between dose escalations (typically 4 weeks minimum) Seek medical advice promptly if experiencing persistent or severe vomiting or diarrhoea, as these can lead to dehydration and acute kidney injury Injection site management: Rotate injection sites between abdomen, thigh, and upper arm Allow the medication to reach room temperature before injecting Use proper injection technique as demonstrated by your healthcare provider Apply a cold compress if irritation occurs Hypoglycaemia prevention: Monitor blood glucose levels as advised, particularly when initiating treatment Recognise early warning signs (trembling, sweating, confusion, palpitations) Carry fast-acting carbohydrates (glucose tablets, sugary drinks) Discuss dose adjustments of other diabetes medications with your clinician For women using oral contraceptives: Be aware that tirzepatide can reduce the effectiveness of oral contraceptives during initiation and after each dose increase Use additional contraception for 4 weeks after starting treatment and for 4 weeks after each dose escalation Consider non-oral contraceptive methods as an alternative General wellbeing strategies: Maintain regular follow-up appointments to monitor treatment response and side effects Keep a symptom diary to identify patterns and triggers Ensure adequate hydration (aim for 68 glasses of water daily) Report persistent or worsening symptoms promptly Report suspected adverse reactions via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk) NICE guidance (NG28 for type 2 diabetes) emphasises the importance of individualised treatment approaches
Some patients may lose fat from the abdomen as their overall weight falls, but body-fat distribution varies between individuals
Increasing both retatrutide and cagrilintide in the same week makes it impossible to determine which compound is causing any side effects that develop
TRICKY, COMPLEX MANUFACTURING The obesity drug market is seen reaching annual sales of around $100 billion by 2030, analysts have said
